- B Riley has resumed coverage of Lantheus Holdings ( NASDAQ: LNTH ) with a buy citing the company's growth trajectory due to the the launch of Pylarify, a prostate-specific membrane antigen (PSMA) targeting positron emission tomography ( PET ) imaging agent.
- The firm has a $102 price target (23% upside based on Wednesday's close).
- Analyst Yuan Zhi noted that Definity, am ultrasound contrast agent, has ~80% market share and generated sales of $121M in 1H22. Pylarify had sales of $223M in the half.
- He added that Lantheus ( LNTH ) recently raised its re venue guidance for the year .
- "Although being agnostic to the particular imaging agent used, the main differentiation factor between approved agents is availability, and this is where we believe LNTH shows a distinct advantage over competing agents," Zhi said in regards to Pylarify.
- Seeking Alpha's Quant Rating views Lantheus ( LNTH ) as a strong buy.
For further details see:
Lantheus Holdings a buy at B Riley on growth spurred by approval of imaging agent